Tech Company Financing Transactions
Clene Nanomedicine Funding Round
Clene Nanomedicine, based in Salt Lake City, secured $42.5 million in investment from private investors.
Transaction Overview
Company Name
Announced On
8/31/2020
Transaction Type
Venture Equity
Amount
$42,500,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to advance its clinical pipeline--particularly the lead nanocatalyst, CNM-Au8--an orally administered therapeutic under investigation for the neurorepair of various neurodegenerative diseases including multiple sclerosis, Parkinson's disease, and ALS, with one Phase 3 trial and four Phase 2 studies ongoing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6550 South Millrock Dr. G50
Salt Lake City, UT 84121
USA
Salt Lake City, UT 84121
USA
Phone
Website
Email Address
Overview
Clene Nanomedicine, Inc. is a privately-held, clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Etherington
Chief Financial Officer
Matthew Gardner
Chief Medical Officer
Robert Glanzman
Chief Scientific Officer
Mark Mortenson
VP - Bus. Development
Michael Hotchkin
Browse more venture capital transactions:
Prev: 8/31/2020: Warby Parker venture capital transaction
Next: 8/31/2020: SWTCH Energy venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs